Thyroid hormones: Beneficial or deleterious for bone?

Calcified Tissue International

Volumn 73, Issue 3, 2003, Pages 205-209

  Lakatos, P ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Bone fracture; Bone loss; Osteoporosis; Thyroid hormones

Indexed keywords

BIOCHEMICAL MARKER; THYROID HORMONE; THYROTROPIN;

BONE DENSITY; BONE GROWTH; BONE METABOLISM; BONE MINERAL; CORRELATION ANALYSIS; DENSITOMETRY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; FRACTURE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; MORTALITY; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THYROID DISEASE; THYROID HORMONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL;

BONE AND BONES; BONE DENSITY; FRACTURES, BONE; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; OSTEOPOROSIS; THYROID HORMONES;

EID: 0141523155     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-002-0027-8     Document Type: Review

References (71)

1. Rizzoli R, Poser J, Bürgi U (1986) Nuclear thyroid hormone receptors in cultured bone cells. Metabolism 35:71-74
2. Sato K, Han DC, Fujii Y, Tsushima T, Shizume K (1987) Thyroid hormone stimulates alkaline phosphatase activity in cultured rat osteoblastic cells (ROS 17/2.8) through 3,5,3′-triiodo-L-thyronine nuclear receptors. Endocrinology 120:1873-1881
3. Abu EO, Bord S, Horner A, Chatterjee VKK, Compston JE (1997) The expression of thyroid hormone receptors in human bone. Bone 21:137-142
4. Britto JM, Fenton AJ, Holloway WR, Nicholson GC (1994) Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 134:169-176
5. Fraichard A, Chassande O, Plateroto M et al. (1997) The T3R alpha gene encoding a thyroid hormone receptor is essential for post-natal development and thyroid hormone production. Embo J 16:4412-4420
6. Gauthier K, Plateroti M, Harvey CB et al. (2001) Genetic analysis reveals different functions for the products for thyroid hormone receptor alpha locus. Mol Cell Biol 21:4746-4748
7. Forrest D, Erway LC, Mg L, Altschuler R, Curran T (1996) Thyroid hormone receptor beta is essential for development of auditory function. Nat Genet 13:354-357
8. Mundy GR, Shapiro JL, Bandelin JG, Canalis EM, Raisz LG (1976) Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 58:529-534
9. Lakatos P, Stern PH (1992) Effects of cyclosporins and transforming growth factor beta on thyroid hormone action in cultured fetal rat limb bones. Calcified Tissue Int 50:123-128
10. Tarjan G, Stern PH (1995) Triiodothyronine potentiates the stimulatory effects of interleukin-1 < beta > on bone resorption and medium interleukin-6 content in fetal rat limb bone cultures. J Bone Miner Res 10:1321-1326
11. Lakatos P, Foldes J, Horvath C, Kiss L, Tatrai A, Takacs G, Tarjan G, Stern PH (1997) Serum IL-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab 82:78-81
12. Lakatos P, Caplice MD, Khanna V, Stern PH (1993) Thyroid hormones increase insulin-like growth factor-I content in the medium of rat bone tissue. J Bone Miner Res 8:1475-1481
13. Lakatos P, Foldes J, Nagy Z, Takács I, Speer G, Horváth S, Mohan S, Baylink DJ, Stern PH (2000) Serum insulin-like growth factor-I, insulin-like growth factor binding proteins, and bone mineral content in hyperthyroidism. Thyroid 5:417-423
14. Svanberg E, Healey J, Mascarenhas D (2001) Anabolic effects of rhIGF-I/IGFBP-3 in vivo are influenced by thyroid status. Eur J Clin Invest 31(4):329-336
15. Stevens DA, Hasserjian RP, Robson H, Siebler T, Shalet GR, Williams GR (2000) Thyroid hormones regulate hypertrophic chondrocyte differentiation and expression of parathyroid hormone-related peptide and its receptor during endochondral bone formation. J Bone Miner Res 15(12):2431-2442
16. Miura M, Tanaka K, Komatsu Y, Suda M, Yasoda A, Sakuma Y, Ozasa A, Nakao K (2002) Thyroid hormones promote chondrocyte differentiation in mouse ATDC5 cells and stimulate endochondral ossification in fetal mouse tibias through iodothyronine deiodinases in the growth plate. J Bone Miner Res 17(3):443-454
17. Toh SH, Claunch BC, Brown PH (1985) Effect of hyperthyroidism and its treatment on bone mineral content. Arch Intern Med 145:833-886
18. Fraser SA, Anderson JB, Smith DA, Wilson GM (1971) Osteoporosis and fractures following thyrotoxicosis. Lancet 1:981-983
19. Meunier PJ, Bianchi GGS, Edouard CM (1972) Bone manifestations of thyrotoxicosis. Orthop Clin North Am 3:745-774
20. Eriksen EF (1986) Normal and pathological remodeling of human trabecular bone: three-dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 7:379-408
21. Mosekilde L, Eriksen EF, Charles P (1990) Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 19:35-63
22. Jastrup B, Mosekilde L, Melsen F, Lund B, Lund B, Sorensen OH (1982) Serum levels of vitamin D metabolites and bone remodeling in hyperthyroidism. Metabolism 31:126-132
23. Cooper DS, Kaplan MM, Ridgway EC, Maloof F, Daniels GH (1979) Alkaline phosphatase isoenzyme patterns in hyperthyroidism. Ann Intern Med 90:164-168
24. Garrel DR, Delmas PD, Malaval L, Tournaire J (1986) Serum bone Gla protein: a marker of bone turnover in hyperthyroidism. J Clin Endocrinol Metab 62:1052-1055
25. MacLeod JM, McHardy KC, Harvey RD, Duncan A, Reid IW, Bewsher PD, Robins SP (1993) The early effects of radioiodine therapy for hyperthyroidism on biochemical indices of bone turnover. Clin Endocrinol 38:49-53
26. Nielsen HE, Mosekilde L, Charles P (1979) Bone mineral content in hyperthyroid patients after combined medical and surgical treatment. Acta Radiol Oncol Radiat Phys Biol 18:122-128
27. Linde J, Friis T (1979) Osteoporosis in hyperthyroidism estimated by photon absorptiometry. Acta Endocrinol 91:437-448
28. Krolner B, Jorgensen JV, Nielsen SP (1983) Spinal bone mineral content in myxoedema and thyrotoxicosis. Effects of thyroid hormone(s) and antithyroid treatment. Clin Endocrinol 18:439-446
29. Rosen CJ, Adler RA (1992) Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 75:1531-1534
30. Grant DJ, McMurdo MET, Mole PA, Paterson CR (1995) Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? Clin Endocrinol 43:339-345
31. Langdahl BL, Loft AG, Eriksen EF, Mosekilde L, Charles P (1996) Bone mass, bone turnover, calcium homeostasis, and body composition in surgically and radioiodine-treated former hyperthyroid patients. Thyroid 6:169-175
32. Langdahl BL, Loft AG, Eriksen EF, Mosekilde L, Charles P (1996) Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid 6:161-168
33. Diamond T, Vine J, Smart R, Butler P (1994) Thyrotoxic bone disease in women: a potentially reversible disorder. Ann Intern Med 120:8-11
34. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KE, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. N Engl J Med 332:767-773
35. Wejda B, Hintze G, Katschinski B, Olbricht T, Benker G (1995) Hip fractures and the thyroid: a case control study. J Intern Med 237:241-247
36. Bauer DC, Ettinger B, Nevitt MC, Stone KL (2001) Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134:561-568
37. Vestergaard P, Rejnmark L, Weeke J, Mosekilde L (2000) Fracture risk in patients treated for hyperthyroidism. Thyroid 10:341-348
38. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P (1998) Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 338:712-718
39. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersback-Nielsen K (1998) Normalization of serum thyrotropin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol 48:285-290
40. Mudde AH, Houben AJ, Nieuwenhuijzen-Kruseman AC (1994) Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol 41:421-424
41. Foldes J, Tarján G, Szathmari M, Varga F, Krasznai I (1993) Bone mineral density in patients with endogenous subclinical hyperthyroidism: Is this thyroid status a risk factor for osteoporosis? Clin Endocrinol 39:521-527
42. Mudde AH, Reijnders FJL, Nieuwenhuijze-Kruseman AC (1992) Peripheral bone density in women with untreated multinodular goitre. Clin Endocrinol 37:35-39
43. Kumeda Y, Inaba M, Tahar H, Kunoka Y, Ishikawa T, Morii H, Nishizawa Y (2000) Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism [in process citation]. J Clin Endocrinol Metab 85:4157-4161
44. Stock JM, Surks MI, Oppenheimer JH (1974) Replacement dosage of L-thyroxine in hypothyroidism. N Engl J Med 290:529-533
45. Paul TL, Kerrigan J, Kelly AM, Braverman, Baran DT (1988) Long-term L-thyroxine is associated with decreased hip bone density in premenopausal women. JAMA 259:3137-3141
46. Diamond T, Nery L, Hales I (1991) A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone density measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 72:1184-1188
47. Lehmke J, Bogner U, Felsenberg D, Peters H, Schleusener H (1992) Determination of bone mineral density by qualitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women. Clin Endocrinol 36:511-517
48. Gonzalez DC, Mautalen CA, Correa PH, el-Tamer E, el-Tamer S (1991) Bone mass in totally thyroidectomized patients. Role of calcitonin deficiency and exogenous thyroid treatment. Acta Endocrinol 124:521-525
49. Stepan JJ, Limanova Z (1992) Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. Bone Miner 17:377-388
50. Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A (1994) Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 78:818-823
51. Garton M, Reid I, Loveridge N, Robins S, Murchison L, Beckett G, Reid D (1994) Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clin Endocrinol 41:747-755
52. Marcocci C, Golia F, Vignali E, Pinchera A (1997) Skeletal muscle integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Res 12:72-77
53. Bauer DC, Nevitt MC, Ettinger B, Stone K (1977) Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Melab 82:2931-2936
54. Franklyn J, Betteridge J, Holder R, Daykin J, Lilley J, Sheppard M (1994) Bone mineral density in thyroxine-treated females with or without a previous history of thyrotoxicosis. Clin Endocrinol 41:425-432
55. Faber J, Galloe AM (1994) Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta analysis. Eur J Endocrinol 130:350-356
56. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY (1996) Effects on bone mass of long-term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81:4278-4289
57. Hanna FW, Pettit RJ, Animari F, Evans WD, Sandeman JH, Lazarus JH (1998) Effect of replacement doses of thyroxine on bone mineral density. Clin Endocrinol 48:229-234
58. Leger J, Ruiz JC, Guibourdenche J, Kindermans C, Garabedian M, Czemichow P (1997) Bone mineral density and metabolism in children with congenital hypothyroidism after prolonged L-thyroxine therapy. Acta Paediatr 86:704-710
59. Ribot C, Tremollieres F, Pouilles JM, Louvet JP (1990) Bone mineral density and thyroid hormone therapy. Clin Endocrinol 33:143-153
60. Solomon BL, Wartofsky L, Burman KD (1993) Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 3:17-23
61. Sheppard MC, Holder R, Franklyn JA (2002) Levothyroxine treatment and occurrence of fracture of the hip. Arch Intern Med 162:338-343
62. Leese GP, Jung RT, Guthrie C, Waugh N, Browning MC (1992) Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol 37:500-503
63. Vestergaard P, Weeke J, Hoeck HC, Nielsen HK, Rungby L, Rejnmark L, Laurberg P, Mosekilde L (2000) Fractures in patients with primary idiopathic hypothyroidism. Thyroid 10:335-340
64. Vestergaard P, Mosekilde L (2002) Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 12:411-419
65. Muller CG, Bayley TA, Harrison JE, Tsang R (1995) Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid 5:81-87
66. Guo CY, Weetman AP, Eastell R (1997) Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol 46:301-307
67. Kung AWC, Yeung SSC (1996) Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 81:1232-1236
68. Schneider DL, Barrett-Connor EL, Morton DJ (1994) Thyroid hormone use and bone mineral density in elderly women. Effect of estrogen. JAMA 271:1245-1249
69. Rosen HN, Moses AC, Gundberg C, Kung VT, Seyedin T, Chen T, Holick M, Greenspan SL (1993) Therapy with parental pamidronate prevents thyroid hormone-induced bone turnover in humans. J Clin Endocrinol Metab 77:664-669
70. Rosen H, Moses A, Garber J, Ross DS, Lee SL, Ferguson V, Chen V, Lee K, Greenspan SL (1998) Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 83:2324-2330
71. Lupoli G, Nuzzo V, Di-Carlo C, Affinito P, Vollery M, Vitale G, Cascone E, Arlotta F, Nappi C (1996) Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. Gynecol Endocrinol 10:343-348